Tan Shali, Zhong Chunyu, Huang Shu, Luo Xujuan, Xu Jin, Fu Xiangsheng, Peng Yan, Tang Xiaowei
Department of Gastroenterology, Affiliated Hospital of Southwest Medical University , Luzhou , China.
Department of Gastroenterology, The People's Hospital of Lianshui , Huaian , China.
Scand J Gastroenterol. 2019 Jul;54(7):811-821. doi: 10.1080/00365521.2019.1638447. Epub 2019 Jul 10.
Lumen-apposing metal stent (LAMS) have been considered as a viable alternative to treat benign gastrointestinal (GI) strictures. We aimed to determine the efficacy and safety of LAMS for benign GI strictures. Medline, Embase, Cochrane, and PubMed databases were searched using the keywords 'benign stricture', 'gastrointestinal stricture', 'lumen-apposing metal stent' and related terms on December 2018. Articles were selected for review by two authors independently according to predefined inclusion criteria and exclusion criteria. A meta-analysis using a random effects model was performed. Six studies with a total of 144 patients were included in the final analysis (60 males, 41.7%). Overall, the pooled technical success rate was 98.3% [95% confidence interval (CI): 0.962-1.004], clinical success rate was 73.8% (95% CI: 0.563-0.912) and adverse events rate was 30.6% (95% CI: 0.187-0.425). The most common complication associated with LAMS for benign GI strictures was migration, and the pooled events rate was 10.9% (95% CI: 0.058-0.160). According to locations of stricture, subgroup analysis was performed in terms of clinical success [Esophagogastric: 63.9% (95% CI: 0.365-0.914); Gastroduodenal: 67.4% (95% CI: 0.421-0.927); Gastrojejunal: 78% (95% CI: 0.638-0.922); Pylorus: 77.6% (95% CI: 0.551-1.002); Colonic: 85.3% (95% CI: 0.515-1.191)]. Although the safety of LAMS placement in benign GI strictures is not very satisfactory, it is associated with a low migration rate. LAMS can achieve clinical symptom improvement or resolution in most patients with benign GI strictures, and it might be an alluring prospect for treating patients with this difficult condition.
管腔贴壁金属支架(LAMS)已被视为治疗良性胃肠道(GI)狭窄的一种可行替代方法。我们旨在确定LAMS治疗良性GI狭窄的疗效和安全性。2018年12月,使用关键词“良性狭窄”“胃肠道狭窄”“管腔贴壁金属支架”及相关术语检索了Medline、Embase、Cochrane和PubMed数据库。两位作者根据预先设定的纳入标准和排除标准独立选择文章进行综述。采用随机效应模型进行荟萃分析。最终分析纳入了6项研究,共144例患者(60例男性,占41.7%)。总体而言,汇总技术成功率为98.3%[95%置信区间(CI):0.962 - 1.004],临床成功率为73.8%(95% CI:0.563 - 0.912),不良事件发生率为30.6%(95% CI:0.187 - 0.425)与LAMS治疗良性GI狭窄相关的最常见并发症是移位,汇总事件发生率为10.9%(95% CI:0.058 - 0.160)。根据狭窄部位,就临床成功率进行了亚组分析[食管胃:63.9%(95% CI:0.365 - 0.914);胃十二指肠:67.4%(95% CI:0.421 - 0.927);胃肠空肠:78%(95% CI:0.638 - 0.922);幽门:77.6%(95% CI:0.551 - 1.002);结肠:85.3%(95% CI:0.515 - 1.191)]。虽然LAMS用于良性GI狭窄置入的安全性不太令人满意,但它移位率较低LAMS可使大多数良性GI狭窄患者的临床症状得到改善或缓解,对于治疗这种疑难病症的患者而言,它可能是一个诱人的前景。